Switch theme
Sign up to access all valuation multiples
Celltrion Pharm Inc is active in the Korean healthcare sector. Its core business includes the manufacture and sale of pharmaceuticals such as heptatonic, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs and antibiotics.
1976
n/a
Last FY Revenue $347M
Last FY EBITDA $41.7M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Celltrion Pharm achieved revenue of $347M and an EBITDA of $41.7M.
Celltrion Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celltrion Pharm valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $347M | XXX | XXX | XXX |
| Gross Profit | XXX | $88.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 26% | XXX | XXX | XXX |
| EBITDA | XXX | $41.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | $27.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 8% | XXX | XXX | XXX |
| Net Profit | XXX | $16.0M | XXX | XXX | XXX |
| Net Margin | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | $79.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Celltrion Pharm's stock price is KRW 49050 (or $36).
Celltrion Pharm has current market cap of KRW 2.13T (or $1.5B), and EV of KRW 2.20T (or $1.6B).
See Celltrion Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Celltrion Pharm has market cap of $1.5B and EV of $1.6B.
Celltrion Pharm's trades at 4.6x EV/Revenue multiple, and 38.4x EV/EBITDA.
Equity research analysts estimate Celltrion Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celltrion Pharm's P/E ratio is not available.
See valuation multiples for Celltrion Pharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 38.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 59.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 97.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 43.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCelltrion Pharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Celltrion Pharm's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celltrion Pharm's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Celltrion Pharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celltrion Pharm acquired XXX companies to date.
Last acquisition by Celltrion Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Celltrion Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Celltrion Pharm founded? | Celltrion Pharm was founded in 1976. |
| Where is Celltrion Pharm headquartered? | Celltrion Pharm is headquartered in South Korea. |
| Is Celltrion Pharm publicy listed? | Yes, Celltrion Pharm is a public company listed on KRX. |
| What is the stock symbol of Celltrion Pharm? | Celltrion Pharm trades under 068760 ticker. |
| When did Celltrion Pharm go public? | Celltrion Pharm went public in 2006. |
| Who are competitors of Celltrion Pharm? | Similar companies to Celltrion Pharm include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Celltrion Pharm? | Celltrion Pharm's current market cap is $1.5B |
| Is Celltrion Pharm profitable? | Yes, Celltrion Pharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
